WO2015101293A1 - 激酶抑制剂及其用途 - Google Patents
激酶抑制剂及其用途 Download PDFInfo
- Publication number
- WO2015101293A1 WO2015101293A1 PCT/CN2014/095615 CN2014095615W WO2015101293A1 WO 2015101293 A1 WO2015101293 A1 WO 2015101293A1 CN 2014095615 W CN2014095615 W CN 2014095615W WO 2015101293 A1 WO2015101293 A1 WO 2015101293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- membered
- methyl
- mmol
- cancer
- Prior art date
Links
- 0 CC(C)[n]1c(cc(cc2F)-c3cc(*)ncc3F)c2nc1C Chemical compound CC(C)[n]1c(cc(cc2F)-c3cc(*)ncc3F)c2nc1C 0.000 description 11
- GZYMDNGZZAXIRP-UHFFFAOYSA-N CC(C)[n]1c(cc(cc2F)-c(cc(C)nc3)c3F)c2nc1C Chemical compound CC(C)[n]1c(cc(cc2F)-c(cc(C)nc3)c3F)c2nc1C GZYMDNGZZAXIRP-UHFFFAOYSA-N 0.000 description 5
- OHQLSJHLUFVRGY-UHFFFAOYSA-N CC(C)[n]1c2cc(-c3cc(N)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(N)ncc3F)cc(F)c2nc1C OHQLSJHLUFVRGY-UHFFFAOYSA-N 0.000 description 2
- CNBVGNPVXGXCNC-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC11CCN(Cc(cn2)cnc2Cl)CC1)=O Chemical compound CC(C)(C)OC(N(C1)CC11CCN(Cc(cn2)cnc2Cl)CC1)=O CNBVGNPVXGXCNC-UHFFFAOYSA-N 0.000 description 1
- KTOLBTXYJHHNPK-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CC2)N(Cc(cn3)cnc3Cl)C2C1)=O Chemical compound CC(C)(C)OC(N1CC(CC2)N(Cc(cn3)cnc3Cl)C2C1)=O KTOLBTXYJHHNPK-UHFFFAOYSA-N 0.000 description 1
- PSDAEKDIOQXLLC-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CC2)NC2C1)=O Chemical compound CC(C)(C)OC(N1CC(CC2)NC2C1)=O PSDAEKDIOQXLLC-UHFFFAOYSA-N 0.000 description 1
- MKFOBMCIEWAALZ-CRAIPNDOSA-N CC(C)(C)OC(N1C[C@H]2N(Cc3cnc(C)nc3)C[C@@]2(C)CC1)=O Chemical compound CC(C)(C)OC(N1C[C@H]2N(Cc3cnc(C)nc3)C[C@@]2(C)CC1)=O MKFOBMCIEWAALZ-CRAIPNDOSA-N 0.000 description 1
- YVDPTFXYMCHRSW-JIPXPUAJSA-N CC(C)[n]1c(cc(cc2F)-c(cc(Nc3ncc(CN(C4)[C@H](C5)[C@@H]4CCN5C(OC(C)(C)C)=O)cn3)nc3)c3F)c2nc1C Chemical compound CC(C)[n]1c(cc(cc2F)-c(cc(Nc3ncc(CN(C4)[C@H](C5)[C@@H]4CCN5C(OC(C)(C)C)=O)cn3)nc3)c3F)c2nc1C YVDPTFXYMCHRSW-JIPXPUAJSA-N 0.000 description 1
- BQANJPOSYKOEAV-HOYKHHGWSA-N CC(C)[n]1c(cc(cc2F)-c(cc(Nc3ncc(CN(C4)[C@H]5[C@@H]4CCNC5)cn3)nc3)c3F)c2nc1C Chemical compound CC(C)[n]1c(cc(cc2F)-c(cc(Nc3ncc(CN(C4)[C@H]5[C@@H]4CCNC5)cn3)nc3)c3F)c2nc1C BQANJPOSYKOEAV-HOYKHHGWSA-N 0.000 description 1
- OFZFTUKCTPPPNX-UHFFFAOYSA-N CC(C)[n]1c2cc(-c(cc(Nc(nc3)ncc3N(CC3)CCN3C3CC3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc(Nc(nc3)ncc3N(CC3)CCN3C3CC3)nc3)c3F)cc(F)c2nc1C OFZFTUKCTPPPNX-UHFFFAOYSA-N 0.000 description 1
- AMXMOGYRSZDUNH-UHFFFAOYSA-N CC(C)[n]1c2cc(-c(cc(Nc(nc3)ncc3N3CCN(C)CC3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc(Nc(nc3)ncc3N3CCN(C)CC3)nc3)c3F)cc(F)c2nc1C AMXMOGYRSZDUNH-UHFFFAOYSA-N 0.000 description 1
- XPCNVDTZWIEBBI-UHFFFAOYSA-N CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN(C4)CC44CCN(C)CC4)cn3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN(C4)CC44CCN(C)CC4)cn3)nc3)c3F)cc(F)c2nc1C XPCNVDTZWIEBBI-UHFFFAOYSA-N 0.000 description 1
- BCBUJLGHZCVHSN-UHFFFAOYSA-N CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN4CC5(CN(C)C5)C4)cn3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN4CC5(CN(C)C5)C4)cn3)nc3)c3F)cc(F)c2nc1C BCBUJLGHZCVHSN-UHFFFAOYSA-N 0.000 description 1
- QSOXQBBNCWBZQZ-YADARESESA-N CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN4C[C@H]5N(C)C[C@H]5C4)cn3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc(Nc3ncc(CN4C[C@H]5N(C)C[C@H]5C4)cn3)nc3)c3F)cc(F)c2nc1C QSOXQBBNCWBZQZ-YADARESESA-N 0.000 description 1
- DBRJMMUFIHNQIL-UHFFFAOYSA-N CC(C)[n]1c2cc(-c(cc([N-]c(nc3)ncc3N(CC3)CCN3C3COC3)nc3)c3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c(cc([N-]c(nc3)ncc3N(CC3)CCN3C3COC3)nc3)c3F)cc(F)c2nc1C DBRJMMUFIHNQIL-UHFFFAOYSA-N 0.000 description 1
- XJWXMRPRDHMURA-UHFFFAOYSA-N CC(C)[n]1c2cc(-c3cc(CCc(nc4)ncc4N(CC4)CCC4N(C)C)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(CCc(nc4)ncc4N(CC4)CCC4N(C)C)ncc3F)cc(F)c2nc1C XJWXMRPRDHMURA-UHFFFAOYSA-N 0.000 description 1
- JUNWPDDDOSNECU-UFHPHHKVSA-N CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN(C5)[C@H]6[C@]5(C)CCNC6)cn4)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN(C5)[C@H]6[C@]5(C)CCNC6)cn4)ncc3F)cc(F)c2nc1C JUNWPDDDOSNECU-UFHPHHKVSA-N 0.000 description 1
- GXAJQPVUVXAXRM-UHFFFAOYSA-N CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5CCC6(CN(C)C6)CC5)cn4)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5CCC6(CN(C)C6)CC5)cn4)ncc3F)cc(F)c2nc1C GXAJQPVUVXAXRM-UHFFFAOYSA-N 0.000 description 1
- NZTCIIRWCBWENG-UHFFFAOYSA-N CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5CCN(C)CC5)cn4)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5CCN(C)CC5)cn4)ncc3F)cc(F)c2nc1C NZTCIIRWCBWENG-UHFFFAOYSA-N 0.000 description 1
- ITJCQYJATCFHIY-ZCYQVOJMSA-N CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5C[C@@H]6OCCN[C@H]6CC5)cn4)ncc3F)cc(F)c2nc1C Chemical compound CC(C)[n]1c2cc(-c3cc(Nc4ncc(CN5C[C@@H]6OCCN[C@H]6CC5)cn4)ncc3F)cc(F)c2nc1C ITJCQYJATCFHIY-ZCYQVOJMSA-N 0.000 description 1
- HRILCAYHMZWZTN-KHPPLWFESA-N CCN(C(C)C)/C(/C)=N\C(C)C Chemical compound CCN(C(C)C)/C(/C)=N\C(C)C HRILCAYHMZWZTN-KHPPLWFESA-N 0.000 description 1
- WRAPMXRCRYGGPC-UHFFFAOYSA-N CCN(CC)c(nc1)cc(-c2cc(F)c3nc(C)[n](C(C)C)c3c2)c1F Chemical compound CCN(CC)c(nc1)cc(-c2cc(F)c3nc(C)[n](C(C)C)c3c2)c1F WRAPMXRCRYGGPC-UHFFFAOYSA-N 0.000 description 1
- OUTTXHCLNTVXFW-UHFFFAOYSA-N CCN(CC1)CCN1c1cnc(Nc(nc2)cc(-c3cc(F)c4nc(C)[n](C(C)C)c4c3)c2F)nc1 Chemical compound CCN(CC1)CCN1c1cnc(Nc(nc2)cc(-c3cc(F)c4nc(C)[n](C(C)C)c4c3)c2F)nc1 OUTTXHCLNTVXFW-UHFFFAOYSA-N 0.000 description 1
- IEVGRAFUZSOGBT-UHFFFAOYSA-N CCN1C2CN(Cc3cnc(Nc(nc4)cc(-c5cc(F)c6nc(C)[n](C(C)C)c6c5)c4[F][F]c4c5nc(C)[n](C(C)C)c5cc(-c(cc(Nc5ncc(CN6CCNCC6)cn5)nc5)c5[F][F]c5c6nc(C)[n](C(C)C)c6cc(-c6cc(Nc(nc7)ncc7N7CCNCC7)ncc6F)c5)c4)nc3)CC1CC2 Chemical compound CCN1C2CN(Cc3cnc(Nc(nc4)cc(-c5cc(F)c6nc(C)[n](C(C)C)c6c5)c4[F][F]c4c5nc(C)[n](C(C)C)c5cc(-c(cc(Nc5ncc(CN6CCNCC6)cn5)nc5)c5[F][F]c5c6nc(C)[n](C(C)C)c6cc(-c6cc(Nc(nc7)ncc7N7CCNCC7)ncc6F)c5)c4)nc3)CC1CC2 IEVGRAFUZSOGBT-UHFFFAOYSA-N 0.000 description 1
- CMOYPFUEZDEQEH-UHFFFAOYSA-N CCN1CCN(Cc2cnc(Nc(cc3-c4cc(F)c5nc(C)[n](C(C)C)c5c4)ncc3F)nc2)CC1 Chemical compound CCN1CCN(Cc2cnc(Nc(cc3-c4cc(F)c5nc(C)[n](C(C)C)c5c4)ncc3F)nc2)CC1 CMOYPFUEZDEQEH-UHFFFAOYSA-N 0.000 description 1
- HQQTWSMGKQUMDV-UHFFFAOYSA-N CN(C1)CC11CCN(Cc(cn2)cnc2Cl)CC1 Chemical compound CN(C1)CC11CCN(Cc(cn2)cnc2Cl)CC1 HQQTWSMGKQUMDV-UHFFFAOYSA-N 0.000 description 1
- CDIYRVMPDGJVGV-UHFFFAOYSA-N CN1CCC2(CN(Cc(cn3)cnc3Cl)C2)CC1 Chemical compound CN1CCC2(CN(Cc(cn3)cnc3Cl)C2)CC1 CDIYRVMPDGJVGV-UHFFFAOYSA-N 0.000 description 1
- KYZMEVJITLXHHP-UHFFFAOYSA-N CN1CCN(Cc(cn2)cnc2Cl)CC1 Chemical compound CN1CCN(Cc(cn2)cnc2Cl)CC1 KYZMEVJITLXHHP-UHFFFAOYSA-N 0.000 description 1
- STFNCBLOLDZYBP-UHFFFAOYSA-N Cc1ncc(CN(CC2)CCC2=O)cn1 Chemical compound Cc1ncc(CN(CC2)CCC2=O)cn1 STFNCBLOLDZYBP-UHFFFAOYSA-N 0.000 description 1
- DTXZJGBCZSLLPQ-UHFFFAOYSA-N Cc1ncc(CN(CC2)CCC2OC)cn1 Chemical compound Cc1ncc(CN(CC2)CCC2OC)cn1 DTXZJGBCZSLLPQ-UHFFFAOYSA-N 0.000 description 1
- OXTORCAXLWKECS-UHFFFAOYSA-N Cc1ncc(CN2CCC3(CN(C)C3)CC2)cn1 Chemical compound Cc1ncc(CN2CCC3(CN(C)C3)CC2)cn1 OXTORCAXLWKECS-UHFFFAOYSA-N 0.000 description 1
- ITKTWKRBXCOJDE-UHFFFAOYSA-N Clc1ncc(CBr)cn1 Chemical compound Clc1ncc(CBr)cn1 ITKTWKRBXCOJDE-UHFFFAOYSA-N 0.000 description 1
- QOKNNUQHCDYWNU-UHFFFAOYSA-N Clc1ncc(CN(C2)CC22CCNCC2)cn1 Chemical compound Clc1ncc(CN(C2)CC22CCNCC2)cn1 QOKNNUQHCDYWNU-UHFFFAOYSA-N 0.000 description 1
- ZSHVLKJKOLRBDH-UHFFFAOYSA-N Clc1ncc(CN2CCC3(CCNCC3)CC2)cn1 Chemical compound Clc1ncc(CN2CCC3(CCNCC3)CC2)cn1 ZSHVLKJKOLRBDH-UHFFFAOYSA-N 0.000 description 1
- VREPFQWTWWOXGO-UHFFFAOYSA-N Clc1ncc(CN2CCC3(CNC3)CC2)cn1 Chemical compound Clc1ncc(CN2CCC3(CNC3)CC2)cn1 VREPFQWTWWOXGO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the invention belongs to the field of medical technology.
- the present invention relates to a CDK4/6 kinase inhibitor, a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, comprising the CDK4/6 kinase inhibitor, which is pharmaceutically acceptable Pharmaceutical preparations, pharmaceutical compositions and kits of the salts, esters thereof, solvates thereof or stereoisomers thereof, and the CDK4/6 kinase inhibitor, pharmaceutically acceptable salts thereof, esters thereof, and solvents thereof Use of the compounds or their stereoisomers.
- the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-associated disease mediated by CDK4/6 kinase.
- tumor is a kind of cell cycle disease (CCD), and regulating or blocking the cell cycle is one of the ways to treat tumors.
- CCD cell cycle disease
- CDKs Cyclin-Dependent-Kinases
- CDKs-centered cell cycle regulatory networks abnormalities in any link will cause cell cycle abnormalities, and ultimately lead to tumors.
- the CDK family currently has 21 subtypes that function by binding to its regulatory subunit cyclins (cyclins).
- cyclins regulatory subunit cyclins
- the function of various subtypes of CDK in addition to acting on the cell cycle, also includes regulation of transcription, DNA repair, differentiation, and programmed cell death.
- the CDKs kinase family Based on the key role of CDKs in regulating tumor cell proliferation and death, the CDKs kinase family provides opportunities and new fields for the discovery and development of anti-tumor drugs.
- the first-generation CDK inhibitors represented by flavopiridol, UCN-01, etc. are "pan-CDK” inhibitors, which block all subtypes of the CDK family in an equivalent manner and show up in clinical trials. Higher toxicity and some inability to achieve effective therapeutic doses have spurred the development of selective CDK inhibitors, which are expected to increase the selectivity of treatment and prevent normal cells from being damaged by some side effects.
- CDK4/6 plays an irreplaceable role in the CDK subtype involved in the cell cycle.
- the cell cycle mutations associated with cancer are mainly present in the G1 and G1/S phase transformations.
- the complex formed by CDK4/6 and CyclinD phosphorylates the tumor suppressor gene Rb product pRb, releasing the bound transcription factor E2F, and initiates The transcription of the gene involved in the S phase causes the cells to pass through the checkpoint and transfer from the G1 phase to the S phase.
- About 80% of human tumors have cyclinD-CDK4/6-INK4-Rb Abnormality of the pathway. The change of this pathway accelerates the G1 phase process, which accelerates the proliferation of tumor cells and gains a survival advantage.
- CDK4/6 has become a new anti-tumor target.
- the advantages of CDK4/6 as an anti-tumor target are: (1) Most proliferating cells rely on CDK2 or CDK4/6 proliferation, but CDK4/6 inhibitors do not exhibit cytotoxicity of "pan-CDK inhibitors", such as Myelosuppression and intestinal reactions. (2) Preclinical experiments show that if the level of cyclin D is increased or P16INK4a is inactivated, the sensitivity of the cells to drugs can be increased. Since the tumor cells have the above phenomenon relative to normal cells, the drug targeting is increased to some extent. Sex.
- CDK inhibitors So far, no CDK inhibitors have been marketed, and some pharmaceutical companies, including Pfizer, Eli Lilly and Novartis, have reported a series of well-selected CDK4/6 inhibitors, which are in clinical trials.
- Pfizer palbociclib
- LY2835219 Phase III
- LEE-011 Phase III
- the present invention provides a novel structure of a selective CDK4/6 inhibitor, and finds that the compound of such structure has good pharmacological effects and can effectively pass the blood-brain barrier, providing a CDK inhibitor as a treatment for brain cancer. possibility.
- One aspect of the invention provides an inhibitor/compound that targets CDK4/6 kinase.
- an exemplary technical solution of the present invention is as follows:
- a 1 and A 2 are each independently selected from nitrogen;
- R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy or a 3-8 membered cycloalkyl optionally substituted by Q 1 , and Q 1 is selected from C 1-6 alkyl or C 1-6 alkane Oxylate
- R 2 is selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, carbamoyl or C 1-6 alkylcarbonylamino;
- R 3 and R 5 are each independently selected from halogen or hydrogen, and at least one of R 3 and R 5 is halogen;
- R 4 is selected from a 3-8 membered heterocyclic group optionally substituted by Q 2 , a 6-14 membered fused heterocyclic group, a 5-8 membered heteroaryl group, a 6-14 membered heteroaryl group, a phenyl group, a naphthyl group. a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclic group;
- Q 2 is selected from the group consisting of amino, hydroxy, halogen, trifluoromethyl, cyano, C 1-6 alkoxy, C 1-6 alkylsulfonyl, C 1-6 alkylsulfonylamino, di C 1-6 An alkylamino group, or a C 1-6 alkyl group optionally substituted by a substituent, a 3-8 membered cycloalkyl group, a 3-8 membered heterocyclic group or a 6-9 membered bridged heterocyclic group, said substituent being selected from the group consisting of Amino, hydroxy, halogen, trifluoromethyl, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylamino, di C 1-6 alkylamino, C 1-6 An alkylsulfonyl group, a 3-8 membered heterocyclic group or a 3-8 membered cycloalkyl group;
- n is selected from 0, 1, 2, 3, 4 or 5.
- a 1 and A 2 are each independently selected from nitrogen;
- R 1 is selected from C 1-4 alkyl or C 1-4 alkoxy
- R 2 is selected from C 1-4 alkyl, C 1-4 alkoxy, cyano, carbamoyl or C 1-4 alkylcarbonylamino;
- R 3 and R 5 are each independently selected from halogen
- R 4 is selected from a 5-6 membered nitrogen-containing heterocyclic group optionally substituted by Q 2 ;
- the "5-6 membered nitrogen-containing heterocyclic group” is preferably a "6-membered nitrogen-containing heterocyclic group"
- Q 2 is selected from amino, hydroxy, halo, trifluoromethyl, cyano, C 1-4 alkoxy, di-C 1-4 alkylamino, or optionally substituted C 1-4 alkyl group substituted by, a 3-6 membered cycloalkyl group or a 3-6 membered heterocyclic group selected from the group consisting of amino, hydroxy, halogen, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1 a -4 alkylamino group, a di C 1-4 alkylamino group or a 3-6 membered cycloalkyl group;
- n is selected from 0.
- a compound according to claim 2 a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, the compound being selected from the group consisting of:
- a 1 and A 2 are each independently selected from nitrogen;
- R 1 is selected from C 1-6 alkyl, C 1-6 alkoxy or a 3-8 membered cycloalkyl optionally substituted by Q 1 wherein Q 1 is selected from C 1-6 alkyl or C 1-6 Alkoxy group;
- R 2 is selected from C 1-6 alkyl, C 1-6 alkoxy, cyano, carbamoyl or C 1-6 alkylcarbonylamino;
- R 3 and R 5 are each independently selected from halogen or hydrogen, and at least one of R 3 and R 5 is halogen;
- R 4 is selected from a 3-8 membered heterocyclic group optionally substituted by Q 2 , a 6-14 membered fused heterocyclic group, a 5-8 membered heteroaryl group, a 6-14 membered heteroaryl group, a phenyl group, a naphthyl group. a 6-12 membered bridged heterocyclic group or a 6-12 membered spiroheterocyclyl group, wherein Q 2 is selected from the group consisting of amino, hydroxy, halogen, trifluoromethyl, cyano, C 1-6 alkyl, C 1-6 alkane An oxy group, a 3-8 membered heterocyclic group or a 6-9 membered bridged heterocyclic group.
- a 1 and A 2 are each selected from nitrogen;
- R 1 is selected from C 1-4 alkyl or C 1-4 alkoxy
- R 2 is selected from C 1-4 alkyl, C 1-4 alkoxy, cyano, carbamoyl or C 1-4 alkylcarbonylamino;
- R 3 and R 5 are each independently selected from halogen
- R 4 is selected from a 5-7 membered heterocyclic group optionally substituted by Q 2 , a 6-11 membered fused heterocyclic group, a 6-11 membered bridged heterocyclic group or a 6-11 membered spiroheterocyclyl group, wherein Q 2 is selected From amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, C 1-4 alkoxy, 5-6 membered heterocyclyl or 7-9 membered bridged heterocyclyl.
- a 1 and A 2 are each selected from nitrogen;
- R 1 is an isopropyl group
- R 2 is selected from the group consisting of methyl, methoxy, cyano, carbamoyl or acetylamino;
- R 3 and R 5 are each fluorine
- R 4 is selected from a 5-6 membered heterocyclic group optionally substituted by Q 2 , wherein Q 2 is selected from the group consisting of amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, C 1-4 alkoxy a 6-membered heterocyclic group or an 8-membered bridged heterocyclic group.
- R 2 is a methyl group
- R 4 is selected from a 5-6 membered nitrogen-containing heterocyclic group optionally substituted by Q 2 , and the 5-6 membered nitrogen-containing heterocyclic group is bonded to the methylene group in the formula (I) via a nitrogen atom, wherein Q 2 is selected from the group consisting of amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, C 1-4 alkoxy or 8-membered nitrogen-containing bridged heterocyclic;
- the 5-6 membered nitrogen-containing heterocyclic group is preferably a 5-6 membered nitrogen-containing heterocyclic group having 1 to 2 nitrogen atoms.
- R 4 is selected from the group consisting of optionally substituted by Q 2 Wherein Q 2 is selected from a C 1-4 alkyl group or an 8-membered nitrogen-containing bridged heterocyclic group.
- a 1 and A 2 are each selected from nitrogen;
- R 1 is an isopropyl group
- R 2 is selected from the group consisting of methyl, methoxy, cyano, carbamoyl or acetylamino;
- R 3 and R 5 are each fluorine
- R 4 is selected from 7-9 membered bridged heterocyclyl optionally substituted by Q 2 , wherein Q 2 is selected from amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, 6-membered heterocyclyl or 8-membered bridge heterocyclic group.
- R 2 is a methyl group
- R 4 is selected from a 7-9 membered nitrogen-containing bridged heterocyclic group optionally substituted by Q 2 , which is bonded to the methylene group in the formula (I) through a nitrogen atom, Wherein Q 2 is selected from the group consisting of amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl or 6-membered nitrogen-containing heterocyclic;
- the 7-9 membered nitrogen-containing bridged heterocyclic group is preferably a 7-9 membered nitrogen-containing bridged heterocyclic group having 1 to 2 nitrogen atoms.
- R 4 is selected from the group consisting of optionally substituted by Q 2 Wherein Q 2 is selected from a C 1-4 alkyl group or a 6-membered nitrogen-containing heterocyclic group.
- a 1 and A 2 are each independently selected from nitrogen;
- R 1 is an isopropyl group
- R 2 is selected from the group consisting of methyl, methoxy, cyano, carbamoyl or acetylamino;
- R 3 and R 5 are each fluorine
- R 4 is selected from 6-10 membered fused heterocyclyl optionally substituted by Q 2 , wherein Q 2 is selected from amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, 6-membered heterocyclyl or 8-membered bridge heterocyclic group.
- R 2 is a methyl group
- R 4 is selected from a 6-10 membered nitrogen-containing fused heterocyclic group containing 1, 2 or 3 identical or different heteroatoms optionally substituted by Q 2 , preferably selected from a nitrogen atom and an oxygen atom, and containing At least one nitrogen atom, the 6-10 membered fused heterocyclic group is bonded to the methylene group of the formula (I) via a nitrogen atom, wherein Q 2 is selected from the group consisting of amino, hydroxy, trifluoromethyl, cyano or C 1 -4 alkyl.
- R 4 is selected from the group consisting of optionally substituted by Q 2 Wherein Q 2 is selected from amino or C 1-4 alkyl.
- a 1 and A 2 are each independently selected from nitrogen;
- R 1 is an isopropyl group
- R 2 is selected from the group consisting of methyl, methoxy, cyano, carbamoyl or acetylamino;
- R 3 and R 5 are each fluorine
- R 4 is selected from 7-11 membered spiroheterocyclyl optionally substituted by Q 2 , wherein Q 2 is selected from amino, hydroxy, trifluoromethyl, cyano, C 1-4 alkyl, 6-membered heterocyclic or 8-membered bridge heterocyclic group.
- R 2 is selected from a methyl group
- R 4 is selected from a 7-11 membered nitrogen-containing spiroheterocyclyl optionally substituted by Q 2 , which is bonded to the methylene group of formula (I) via a nitrogen atom, Wherein Q 2 is selected from the group consisting of amino, hydroxy, trifluoromethyl, cyano or C 1-4 alkyl;
- the 7-11 membered nitrogen-containing spiroheterocyclyl group is preferably a 7-11 membered nitrogen-containing spiroheterocyclyl group having 1 to 2 nitrogen atoms.
- R 4 is selected from the group consisting of optionally substituted by Q 2 Wherein Q 2 is selected from C 1-4 alkyl.
- the compound according to item 1 a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, which is selected from the compounds shown in Table A.
- the invention also relates to various uses of the disclosed compounds. Accordingly, the present invention also relates to the following exemplary technical solutions:
- a pharmaceutical composition comprising the compound according to any one of aspects 1 to 18, a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, and optionally a One or more pharmaceutically acceptable carriers.
- composition of embodiment 19 further comprising one or more additional anti-neoplastic agents and/or immunosuppressive agents.
- the additional anti-tumor agent and/or immunosuppressive agent is selected from one or more of the following: methotrexate, capecitabine, gemcitabine, Deoxyfluorouridine, pemetrexed disodium, pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, Herceptin, bevacizum Anti-rituximab, trastuzumab, paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, Bleomycin, letrozole, tamoxifen, fulvestrant, triclinin, flutamide, leuprolide, anastrozole, ifosfamide, busulfan, cyclophosphamide, card Mustastine, nitustine, semustine, nitrogen mustard,
- the cancer-related disease is selected from the group consisting of a brain tumor, a lung cancer, a squamous cell carcinoma, a bladder cancer, a stomach cancer, an ovarian cancer, a peritoneal cancer, a pancreatic cancer, a breast cancer, a head and a neck cancer, and a child.
- Cervical cancer endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female genital tract cancer, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer , skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.
- claim 22 or 23 wherein the subject is a mammal, such as a bovine, equine, ovine, porcine, canine, feline, rodent , primates; wherein, a particularly preferred subject is a human.
- a mammal such as a bovine, equine, ovine, porcine, canine, feline, rodent , primates; wherein, a particularly preferred subject is a human.
- the medicament further comprises one or more additional anti-neoplastic agents and/or immunosuppressive agents; preferably, the additional anti-tumor agent and/or Or the immunosuppressive agent is selected from one or more of the following: methotrexate, capecitabine, gemcitabine, deoxyfluorouridine, pemetrexed disodium, pazopanib, imatinib , erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, dosi Hesai, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bo Levomycin, letrozole, tamoxifen, fulvestrant, triclinin, flutamide, leuprolide, anastrozole,
- a method of treating and/or preventing a cancer-associated disease mediated by a CDK4/6 kinase comprising a therapeutically and/or prophylactically effective amount of a compound of any one of the methods 1 to 18, which is pharmaceutically acceptable A salt, an ester thereof, a solvate thereof, or a stereoisomer thereof, or a pharmaceutical composition according to any one of the schemes 19-21, is administered to a subject in need thereof.
- the cancer-related disease is selected from the group consisting of a brain tumor, a lung cancer, a squamous cell carcinoma, a bladder cancer, a stomach cancer, an ovarian cancer, a peritoneal cancer, a pancreatic cancer, a breast cancer, a head and a neck cancer, and a child.
- Cervical cancer endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female genital tract cancer, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer , skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.
- the subject is a mammal, such as a bovine, equine, ovine, porcine, canine, feline, rodent , primates; wherein, a particularly preferred subject is a human.
- the compound according to claim 30, a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, wherein the cancer-related disease is selected from the group consisting of brain tumor, lung cancer, squamous cell carcinoma , bladder cancer, stomach cancer, ovarian cancer, Peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female genital cancer, carcinoma in situ , lymphoma, neurofibromatosis, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, colloid Tumor or sarcoma.
- the cancer-related disease is selected from the group consisting of brain tumor, lung cancer, squamous cell
- the formulation is for administration in vivo or in vitro; for example, the formulation is administered to a subject (eg, a mammal; eg, a bovine, an equine, an estro, a porcine, canine, feline, rodent, primate; for example, a human, to reduce or inhibit CDK4 and/or CDK6 kinase activity in a cell in a subject; or The formulation is administered to an in vitro cell (eg, a cell line or a cell from a subject, such as a cancer cell) to reduce or inhibit CDK4 and/or CDK6 kinase activity in cells in vitro.
- a subject eg, a mammal; eg, a bovine, an equine, an estro, a porcine
- canine feline, rodent, primate
- a human for example, a human
- the formulation is administered to an in vitro cell (eg, a cell line or a cell from
- the cell is selected from the group consisting of a brain tumor cell, a lung cancer cell, a squamous cell carcinoma cell, a bladder cancer cell, a gastric cancer cell, an ovarian cancer cell, a peritoneal cancer cell, and a pancreatic cancer cell.
- a method of reducing or inhibiting CDK4 and/or CDK6 kinase activity in a cell which comprises administering to said cell an effective amount of a compound according to any one of aspects 1 to 18, a pharmaceutically acceptable salt thereof, an ester thereof , their solvates or their stereoisomers.
- the cell is a subject (eg, a mammal; eg, a bovine, equine, ovine, porcine, canine family) a cell in the body of an animal, a feline, a rodent, a primate; for example, a human; or the method is used in vitro, for example, the cell is a cell in vitro (eg, a cell line or a subject) Cells such as cancer cells).
- a subject eg, a mammal; eg, a bovine, equine, ovine, porcine, canine family
- a cell in the body of an animal eg, a feline, a rodent, a primate; for example, a human
- the method is used in vitro, for example, the cell is a cell in vitro (eg, a cell line or a subject) Cells such as cancer cells).
- the cell is selected from the group consisting of a brain tumor cell, a lung cancer cell, a squamous cell carcinoma cell, a bladder cancer cell, a gastric cancer cell, an ovarian cancer cell, a peritoneal cancer cell, and a pancreatic cancer cell.
- the compound of claim 40 a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, for administration in vivo or in vitro; for example, the preparation is administered to a subject (for example, a mammal; for example, a bovine, an equine, a sheep, a porcine, a canine, a feline, a rodent, a primate; for example, a human, to reduce or inhibit a test.
- a mammal for example, a bovine, an equine, a sheep, a porcine, a canine, a feline, a rodent, a primate; for example, a human, to reduce or inhibit a test.
- CDK4 and/or CDK6 kinase activity in cells in vivo alternatively, the formulation is administered to cells in vitro (eg, cell lines or cells from a subject, such as cancer cells) to reduce or inhibit CDK4 and/or cells in vitro Or CDK6 kinase activity.
- cells in vitro eg, cell lines or cells from a subject, such as cancer cells
- the compound of claim 40 or 41 a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, wherein the cell is selected from the group consisting of a brain tumor cell, a lung cancer cell, and a squamous epithelium.
- Cell cancer cells bladder cancer cells, gastric cancer cells, ovarian cancer cells, peritoneal cancer cells, pancreatic cancer cells, breast cancer cells, head and neck cancer cells, cervical cancer cells, endometrial cancer cells, rectal cancer cells, liver cancer cells, kidney Cancer cells, esophageal adenocarcinoma cells, esophageal squamous cell carcinoma cells, prostate cancer cells, female genital tract cancer cells, carcinoma cells in situ, lymphoma cells, neurofibromatosis cells, thyroid cancer cells, bone cancer cells, skin cancer cells , brain cancer cells, colon cancer cells, testicular cancer cells, gastrointestinal stromal tumors Cells, prostate tumor cells, mast cell tumor cells, multiple myeloma cells, melanoma cells, glioma cells or sarcoma cells.
- kits for reducing or inhibiting CDK4 and/or CDK6 kinase activity in a cell comprising the compound of any one of claims 1 to 18, a pharmaceutically acceptable salt thereof, The esters, solvates thereof or stereoisomers thereof, and optionally also include instructions for use.
- the "Me” is a methyl group.
- the wavy line in the substituent The meaning is that the group of the substituent at the position of the wavy line is linked to the group of the main chain (for example, a benzene ring) by a chemical bond.
- halogen atom as used in the present invention includes, for example, a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- C 1-6 alkyl group described in the present invention may be linear or branched, and includes, for example, "C 1-4 alkyl group", “C 1-3 alkyl group” and the like, and specific examples thereof include, but are not limited to, : methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-methylpropyl, 1-methylpropyl, 1,1-dimethylethyl, n-pentyl, 3-methyl Butyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, n-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1 -methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3- Dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl
- C 1-6 alkoxy group, C 1-6 alkylcarbonylamino group, C 1-6 alkylsulfonyl group, C 1-6 alkylsulfonylamino group, C 1-6 alkylamino group, "Di-C 1-6 alkylamino" means C 1-6 alkyl-O-, C 1-6 alkyl-C(O)NH-, C 1-6 alkyl-SO 2 -, C 1- a group formed by 6 alkyl-SO 2 NH-, C 1-6 alkyl-NH-, (C 1-6 alkyl) 2 -N-, wherein "C 1-6 alkyl" is as defined above Said.
- DiC 1-4 alkylamino means C 1-4 alkyl-O-, C 1-4 alkyl-C(O)NH-, C 1-4 alkyl-SO 2 -, C 1- a group formed by a 4- alkyl-SO 2 NH-, C 1-4 alkyl-NH-, (C 1-4 alkyl) 2 -N-form wherein "C 1-4 alkyl” is as defined above Said.
- the "3-8 membered cycloalkyl group" as used in the present invention means that the alkane moiety of 3 to 8 carbon atoms is removed by a hydrogen atom-derived cyclic alkyl group, and includes, for example, "3-6 membered cycloalkyl group", 4-6 membered cycloalkyl” and the like. Examples thereof include, but are not limited to, cyclopropyl, cyclobutane, cyclopentyl, cyclohexane, cycloheptyl, cyclooctyl, and the like.
- the “3-8 membered heterocyclic group” as used in the present invention includes, for example, “3-7 membered heterocyclic group", "3-6 membered heterocyclic group”, “4-7 membered heterocyclic group”, “4- 6-membered heterocyclic group”, "5-7 membered heterocyclic group”, “5-6 membered heterocyclic group”, “5-6 membered nitrogen-containing heterocyclic group”, “6-membered heterocyclic group”, “6-membered member” Nitrogen-containing heterocyclic group" and the like.
- Specific examples include, but are not limited to, aziridine, 2H-azepine, diaziryl, 3H-diazapropenyl, azetidinyl, 1,4-dioxo Heterocyclohexane, 1,3-dioxanyl, 1,3-dioxolyl, 1,4-dioxadienyl, tetrahydrofuranyl, dihydropyrrolyl , pyrrolidinyl, imidazolidinyl, 4,5-dihydroimidazolyl, pyrazolidinyl, 4,5-dihydropyrazolyl, 2,5-dihydrothienyl, tetrahydrothiophenyl, 4,5 -dihydrothiazolyl, piperidinyl, piperazinyl, morpholinyl, hexahydropyrimidinyl, hexahydropyridazinyl, 4,5-dihydr
- the term "linked to a methylene group in the formula (I) by a nitrogen atom” as used in the present invention means a nitrogen-containing group (for example, a nitrogen-containing heterocyclic group such as a "5-6 membered nitrogen-containing heterocyclic group” or "6-membered nitrogen-containing heterocyclic group”; nitrogen-containing fused heterocyclic group such as “6-10 membered nitrogen-containing fused heterocyclic group”; nitrogen-containing bridged heterocyclic group such as "7-9 membered nitrogen-containing bridged heterocyclic group” Or “8-membered nitrogen-containing bridged heterocyclic group”; a nitrogen-containing spiroheterocyclyl group such as "7-11 membered nitrogen-containing spiroheterocyclyl" is bonded to a methylene group through a nitrogen atom.
- a nitrogen-containing heterocyclic group such as a "5-6 membered nitrogen-containing heterocyclic group” or "6-membered nitrogen-containing heterocyclic group
- the fused ring of the present invention refers to a fused ring structure formed by two or more cyclic structures sharing two adjacent atoms (ie, sharing one bond).
- the bridge ring of the present invention refers to a bridge ring structure formed by two or more ring structures sharing two non-adjacent carbon atoms with each other.
- the spiro ring according to the present invention refers to a spiro ring structure in which two or more ring structures are connected to each other by a carbon atom.
- the "6-14 membered fused heterocyclic group" as used in the present invention means that two or more cyclic structures share two adjacent atoms (ie, share a bond) to form at least one hetero atom.
- a fused ring structure of 6 to 14 ring atoms including, for example, "6-11 membered fused heterocyclic group", “6-10 membered fused heterocyclic group”, “7-10 membered fused heterocyclic group”, “9- A 10-membered fused heterocyclic group, a "6-10 membered nitrogen-containing fused heterocyclic group", and the like.
- the "5-8 membered heteroaryl group” as used in the present invention includes, for example, "5-7 membered heteroaryl group", "5-6 membered heteroaryl group” and the like. Specific examples include, but are not limited to, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1, 2,3-Triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl 1,3,4-oxadiazolyl, pyridyl, 2-pyridone, 4-pyridone, pyrimidinyl, 1,4-dioxadienyl, 2H-1,2-oxazinyl 4H-1,2-oxazinyl, 6H-1,2-
- 6-14 membered fused heteroaryl group as used in the present invention means that two or more cyclic structures share two adjacent atoms (ie, share one bond) to form at least one hetero atom.
- 6-14 ring atomic, aromatic fused ring structures including, for example, "6-10 membered heteroaryl", “7-10 membered heteroaryl”, “9-10 membered heteroaryl” "Wait.
- Specific examples include, but are not limited to, benzofuranyl, benzoisofuranyl, benzothienyl, fluorenyl, isoindole, benzoxazolyl, benzimidazolyl, oxazolyl, benzotriazole , quinolyl, 2-quinolinone, 4-quinolinone, 1-isoquinolinone, isoquinolyl, acridinyl, phenanthryl, benzoxazinyl, pyridazinyl, quinazoline A phenyl group, a quinoxalinyl group, a phenol sulfinyl group, an acridinyl group, a fluorenyl group, a naphthyridinyl group, a phenazine, a phenothiazine, and the like.
- the "6-12-membered bridged heterocyclic group" as used in the present invention means a bridged ring structure of 6 to 12 ring atoms having at least one hetero atom formed by sharing two non-adjacent atoms in any two rings.
- the hetero atom is selected from the group consisting of N, S, O, CO, SO, and/or SO 2 and the like.
- the "6-12 member spiroheterocyclyl group" as used in the present invention means a spiro ring structure of 6 to 12 ring atoms having at least two rings sharing one atom and having at least one hetero atom, said hetero atom. It is selected from N, S, O, CO, SO, and/or SO 2 and the like.
- the invention also provides a preparation method of the compound of the formula (I'), which comprises, but is not limited to, the following route (wherein the abbreviations represent the following definitions: DCM: dichloromethane; DIPEA: N, N-diisopropyl Ethylethylamine; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; EA: ethyl acetate; HATU: 2-(7-azobenzotriazole)-N,N, N',N'-tetramethylurea hexafluorophosphate; MeOH: methanol; NBS: N-bromosuccinimide; PE: petroleum ether; THF: tetrahydrofuran; Xant-phos: 4,5 - bisdiphenylphosphino-9,9-dimethyloxaxan; x-phos: 2-dicyclohexylphosphor-2',4',6'-triiso
- R 1 , R 2 , R 3 , R 4 , R 5 , n, A 1 , A 2 are as described above,
- X represents halogen, is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and the halogenating agent is selected from the group consisting of: I 2 , Br 2 .
- the raw material 1 and the organic base are dissolved in an organic solvent, and the raw material 2 is slowly added dropwise under a low temperature condition. After the stirring reaction is completed, the reaction mixture is extracted, the organic layer is dried, and concentrated to obtain an intermediate 1, wherein the organic solvent is preferably DCM or 1, 4-Dioxane, the organic base is preferably triethylamine.
- the organic solvent is preferably DCM or 1, 4-Dioxane
- the organic base is preferably triethylamine.
- the intermediate 1, the raw material 3 and the organic base are dissolved in an organic solvent, and phosphorus oxychloride is added dropwise. After the reaction is completed, the alkali is added, the pH of the reaction mixture is adjusted to neutral, extracted, and the organic phase is separated and dried.
- Intermediate 2 wherein the organic solvent is preferably dichloromethane or 1,2-dichloroethane, and the organic base is preferably triethylamine.
- the intermediate 2 is dissolved in an organic solvent, potassium tert-butoxide is added, and the mixture is heated to 100 ° C for 2 hours. After the reaction is completed, water is quenched, the reaction mixture is extracted, the organic phase is dried, and the residue is purified by column chromatography.
- Intermediate 3 wherein the organic solvent is preferably DCM.
- the intermediate 3 and the pinacol borate are dissolved in an organic solvent, and palladium acetate, tricyclohexylphosphoric acid and potassium acetate are added, and the reaction is heated under nitrogen. After the reaction is completed, water and an organic solvent are added for extraction, and the organic layer is dried, concentrated, and subjected to column chromatography to obtain Intermediate 4, wherein the organic solvent is preferably DMF or 1,4-dioxane.
- the organic solvent is preferably DMF or 1,4-dioxane.
- the starting material 4 and the intermediate 4 are dissolved in an organic solvent, an inorganic base and tetrakis(triphenylphosphine)palladium are added, and the reaction is completed by heating under nitrogen atmosphere, water is added, the reaction mixture is extracted, the organic phase is dried, and concentrated, and the column layer is applied.
- the intermediate 5 is isolated, wherein the organic solvent is preferably 1,4 dioxane or DMF.
- the raw material 5 is dissolved in an organic solvent, and benzoyl peroxide and NBS are added to heat to the end of the reaction, and the filtrate is concentrated. The residue is subjected to column chromatography to give the intermediate 6 wherein the organic solvent is preferably carbon tetrachloride.
- the intermediate 6 and the starting material 6 are dissolved in an organic solvent, and an inorganic base is added to the reaction at room temperature until the reaction is completed.
- the mixture is filtered, and the filtrate is concentrated. The residue is purified by column chromatography.
- the raw material 6 is a primary or secondary amine.
- the "pharmaceutically acceptable salt" of the compound of the formula (I') or the formula (I) of the present invention means an acidic functional group (for example, -COOH, -OH, which is present in the compound of the formula (I') or the formula (I).
- a salt formed with a suitable inorganic or organic cation including a salt formed with an alkali metal or an alkaline earth metal, an ammonium salt, and a salt formed with a nitrogen-containing organic base; and formula (I') Or a salt formed by a basic functional group (for example, -NH 2 or the like) present in the compound of the formula (I) with a suitable inorganic or organic anion (acid), and an inorganic acid, and an organic carboxylic acid.
- the "ester” of the compound of the formula (I') or the formula (I) of the present invention means an ester which is formed by esterification reaction with an alcohol when a compound of the formula (I') or the compound of the formula (I) is present;
- a compound of the formula (I') or the formula (I) has a hydroxyl group, it is esterified by an esterification reaction with an organic acid, an inorganic acid, an organic acid salt or the like.
- the ester can be hydrolyzed to form the corresponding acid or alcohol in the presence of an acid or a base.
- the "solvate” of the compound of the formula (I') or the formula (I) of the present invention means a substance which is formed by association with a solvent molecule.
- the solvent may be an organic solvent (e.g., methanol, ethanol, propanol, acetonitrile, etc.), water, or the like.
- a compound of formula (I') or formula (I) of the present invention can form an ethanolate with ethanol and form a hydrate with water.
- the “stereoisomers” of the compounds of the invention are classified into conformational and conformational isomers, while the configurational isomerism is further divided into cis-trans isomerization and optical isomerism.
- Conformational isomerism refers to a stereoisomerism in which organic molecules of a certain configuration cause different arrangement of atoms or groups of molecules in space due to the rotation or distortion of carbon and carbon single bonds. Common alkanes and rings are common. The structure of an alkane compound, such as the chair conformation and the ship conformation that appear in the cyclohexane structure.
- Stepoisomer means that when the compound of the invention contains one or more asymmetric centers, it can be used as a racemate and a racemic mixture, a single enantiomer, a mixture of diastereomers and a single Diastereomers.
- the compounds of the invention have asymmetric centers, each of which will independently produce two optical isomers, the scope of the invention including all possible optical isomers and mixtures of diastereomers and pure or partially Pure compound. If the compound of the present invention contains an olefinic double bond, the present invention includes a cis isomer and a trans isomer unless otherwise specified.
- the compounds of the present invention may exist in tautomeric forms which have different hydrogen attachment points by displacement of one or more double bonds.
- a ketone and its enol form are keto-enol tautomers.
- Each tautomer and mixtures thereof are included in the compounds of the invention.
- All enantiomers, diastereomers, racemic isomers, cis and trans isomers, tautomers, geometric isomers, and diasters of the compounds of formula (I') or formula (I) Isomers and mixtures thereof are included within the scope of the invention.
- the invention further claims to include a compound of formula (I') or formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof, and optionally one or more A pharmaceutical composition of a pharmaceutically acceptable carrier.
- Drug group The compound can be formulated into any of the pharmaceutically acceptable dosage forms.
- the pharmaceutical composition may also be administered to a patient or subject in need of such treatment by any suitable mode of administration, such as oral, parenteral, rectal or pulmonary administration.
- the pharmaceutical composition can be prepared into a conventional solid preparation such as a tablet, a capsule, a pill, a granule, etc.; or an oral liquid preparation such as an oral solution or an oral suspension. , syrup, and the like.
- the pharmaceutical composition can be prepared as an injection, including an injection, a sterile powder for injection, and a concentrated solution for injection.
- the injection can be produced by a conventional method in the prior art, and when the injection is formulated, an additional agent may be added, or a suitable additive may be added depending on the nature of the drug.
- the pharmaceutical composition can be formulated as a suppository or the like.
- the pharmaceutical composition can be formulated as an inhalant or a spray.
- the pharmaceutical composition of the present invention may further comprise one or more than the compound of the formula (I') or the formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof.
- additional anti-tumor agents and / or immunosuppressive agents may further comprise one or more than the compound of the formula (I') or the formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof.
- the antitumor agent and/or immunosuppressive agent including but not limited to methotrexate, capecitabine, gemcitabine, deoxyfluorouridine, pemetrexed disodium, pazopanib, imatin Nie, erlotinib, lapatinib, gefitinib, vandetanib, Herceptin, bevacizumab, rituximab, trastuzumab, paclitaxel, vinorelbine, multiple Citadine, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, tamoxifen, fulvestrant, tricepsin Lin, flutamide, leuprolide, anastrozole, ifosfamide, busulfan, cyclophosphamide, carmustine, nimustine, semustine, nitrogen mustard, melphalan, tumor Ning, carbo
- the present invention also provides a compound represented by the formula (I') or the formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof or a pharmaceutical composition of the present invention
- a cancer-associated disease mediated by CDK4/6 kinase in a subject.
- the cancer-related disease is selected from the group consisting of brain tumor, lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer.
- endometrial cancer rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female genital tract cancer, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer, skin Cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma or sarcoma.
- the subject or patient may be any animal, preferably a mammal, such as a bovine, equine, ovine, porcine, canine, feline, rodent, spirit. Long-lived animals. Among them, a particularly preferred subject is a human.
- the invention also provides a method of treating and/or preventing a cancer-associated disease mediated by CDK4/6 kinase, which comprises treating A therapeutically and/or prophylactically effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof or a pharmaceutical composition of the invention, administered to a subject in need thereof .
- an effective amount refers to an amount sufficient to achieve, or at least partially achieve, a desired effect.
- an effective amount to prevent a disease eg, a cancer-associated disease mediated by CDK4/6 kinase
- an effective amount to prevent, arrest, or delay the onset of a disease eg, a cancer-associated disease mediated by CDK4/6 kinase
- treating an effective amount of a disease is meant an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease. Determination of such an effective amount is well within the capabilities of those skilled in the art.
- the amount effective for therapeutic use will depend on the severity of the condition to be treated, the overall condition of the patient's own immune system, the general condition of the patient such as age, weight and sex, the mode of administration of the drug, and other treatments for simultaneous administration. and many more.
- a compound or pharmaceutical composition of the invention can be administered to a subject in need thereof in any suitable manner, in any suitable dosage form.
- a compound or pharmaceutical composition of the invention can be administered to a subject in need thereof by oral, parenteral, rectal or pulmonary administration.
- the compound or pharmaceutical composition of the present invention may be a tablet, a capsule, a pill, a granule, a solution, a suspension, a syrup, an injection (including an injection, a sterile powder for injection and a concentrated solution for injection), and a suppository. , inhalation or spray.
- the method of the invention can be used in a variety of subjects, preferably mammals, such as bovine, equine, ovine, porcine, canine, feline, rodent, primate Animals.
- mammals such as bovine, equine, ovine, porcine, canine, feline, rodent, primate Animals.
- a particularly preferred subject is a human.
- the methods of the invention can be used to treat and/or prevent a variety of cancer-associated diseases mediated by CDK4/6 kinase, including but not limited to brain tumors, lung cancer, squamous cell carcinoma, bladder Cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female Genital tract cancer, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple bone marrow Tumor, melanoma, glioma or sarcoma.
- CDK4/6 kinase including but not limited to brain tumors, lung cancer, squamous cell carcinoma, bladder Cancer, gas
- the method of the present invention may further comprise, The subject administers one or more additional anti-tumor agents and/or immunosuppressive agents.
- the compounds of the invention may be used in combination with one or more additional anti-neoplastic agents and/or immunosuppressive agents.
- the additional anti-tumor agent and/or immunosuppressive agent is selected from one or more of the group consisting of methotrexate, capecitabine, gemcitabine, deoxyfluorouridine , pemetrexed disodium, pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab Monoclonal antibody, trastuzumab, Paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, tamoxifen, Fulvestrant, triclinin, flutamide, leuprolide, anastrozole, ifosfamide, busulfan, cyclophosphamide, carmustine, nimustine, semustine
- the compounds of the invention and the additional anti-neoplastic agents and/or immunosuppressive agents can be administered in any order.
- the additional anti-neoplastic agent and/or immunosuppressive agent can be administered to the subject prior to, concurrently with, or subsequent to administration of the compound of the invention.
- the present invention also provides the use of a compound of the formula (I') or the formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof for the preparation of a preparation, Formulations are used to reduce or inhibit CDK4 and/or CDK6 kinase activity in cells.
- the formulation is for administration in vivo or in vitro.
- the formulation can be administered to a subject (eg, a mammal; eg, a bovine, equine, ovine, porcine, canine, feline, rodent, primate) For example, human) to reduce or inhibit CDK4 and/or CDK6 kinase activity in cells in a subject; alternatively, the formulation can be administered to cells in vitro (eg, cell lines or cells from a subject such as cancer) Cells) to reduce or inhibit CDK4 and/or CDK6 kinase activity in cells in vitro.
- a subject eg, a mammal; eg, a bovine, equine, ovine, porcine, canine, feline, rodent, primate
- a subject eg, a mammal; eg, a bovine, equine, ovine, porcine, canine, feline, rodent, primate
- the formulation can be administered to cells in vitro (eg, cell lines or cells
- the cell is selected from the group consisting of a brain tumor cell, a lung cancer cell, a squamous cell carcinoma cell, a bladder cancer cell, a gastric cancer cell, an ovarian cancer cell, a peritoneal cancer cell, a pancreatic cancer cell, a breast cancer cell, Head and neck cancer cells, cervical cancer cells, endometrial cancer cells, rectal cancer cells, liver cancer cells, renal cancer cells, esophageal adenocarcinoma cells, esophageal squamous cell carcinoma cells, prostate cancer cells, female reproductive tract cancer cells, in situ Cancer cells, lymphoma cells, neurofibromatosis cells, thyroid cancer cells, bone cancer cells, skin cancer cells, brain cancer cells, colon cancer cells, testicular cancer cells, gastrointestinal stromal tumor cells, prostate tumor cells, mast cells Tumor cells, multiple myeloma cells, melanoma cells, glioma cells or sarcoma cells.
- the invention also provides a method of reducing or inhibiting CDK4 and/or CDK6 kinase activity in a cell comprising administering to said cell an effective amount of a compound of the invention, a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof Or their stereoisomers.
- the method is for use in vivo, for example, the cell is a subject (eg, a mammal; eg, a bovine, an equine, a sheep, a porcine, a canine, a cat) a cell, a rodent, a primate; for example, a human; or the method is for use in vitro, for example, the cell is a cell in vitro (eg, a cell line or a cell from a subject, such as a cancer) cell).
- a subject eg, a mammal; eg, a bovine, an equine, a sheep, a porcine, a canine, a cat
- a cell eg.g, a rodent, a primate
- the cell is a cell in vitro (eg, a cell line or a cell from a subject, such as a cancer) cell).
- the cell is selected from the group consisting of a brain tumor cell, a lung cancer cell, a squamous cell carcinoma cell, a bladder cancer cell, a gastric cancer cell, an ovarian cancer cell, a peritoneal cancer cell, a pancreatic cancer cell, a breast cancer cell, Head and neck cancer cells, cervical cancer cells, endometrial cancer cells, rectum Cancer cells, liver cancer cells, renal cancer cells, esophageal adenocarcinoma cells, esophageal squamous cell carcinoma cells, prostate cancer cells, female genital cancer cells, carcinoma cells in situ, lymphoma cells, neurofibromatosis cells, thyroid cancer cells, Bone cancer cells, skin cancer cells, brain cancer cells, colon cancer cells, testicular cancer cells, gastrointestinal stromal tumor cells, prostate tumor cells, mast cell tumor cells, multiple myeloma cells, melanoma cells, glioma Cell or sarcoma cells.
- the present invention also provides a kit for reducing or inhibiting CDK4 and/or CDK6 kinase activity in a cell, the kit comprising the compound of the present invention, a pharmaceutically acceptable salt thereof, an ester thereof, and a solvent thereof Compounds or their stereoisomers, and optionally also instructions for use.
- the compound of the formula (I') or the formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a solvate thereof or a stereoisomer thereof thereof has excellent CDK4/6 kinase inhibitory activity;
- Test substance Compounds 1, 13, and 14, of the present invention, chemical names, structural formulas, and preparation methods are shown in the preparation examples of the respective compounds.
- a DMSO stock solution of 10 mM test substance was taken and diluted with DMSO to prepare a solution having a concentration of 50 ⁇ M as a mother liquid.
- the above mother liquor was diluted four times in DMSO to prepare a solution of 12.5 ⁇ M, 3.125 ⁇ M, 0.78 ⁇ M, 0.195 ⁇ M, 0.0488 ⁇ M, 12.2 nM, 3 nM, 0.76 nM, 0.19 nM, and then buffered with 1 ⁇ kinase for each concentration.
- the solution was diluted 10 times to prepare a 5-fold compound solution.
- the reaction was terminated by adding 25 ⁇ L of stop solution to each of the corresponding wells.
- the Caliper instrument reads the data and calculates the inhibition rate by the following formula, and then performs curve fitting using GraphPad 5.0 software to obtain an IC 50 value.
- Inhibition rate (maximum - sample value) / (maximum - minimum value) ⁇ 100
- the maximum value a positive control without a test substance; the minimum value: a negative control without an enzyme.
- Test substance The chemical name and preparation method of the compound of the present invention can be found in the preparation examples of the respective compounds.
- the washing solution having a mother liquor concentration of 20 times was diluted with ultrapure water to a double washing solution.
- the BrdU detection antibody having a mother liquid concentration of 100 times was diluted with a detection antibody dilution to a 1-fold detection antibody solution.
- the anti-mouse IgG having a mother liquor concentration of 100-fold was diluted with an HRP-labeled antibody dilution to a 1-fold HRP-labeled secondary antibody solution.
- the BrdU solution having a mother liquor concentration of 1000-fold was diluted into a 10-fold BrdU solution using a cell-specific medium.
- Formulation test compound mother liquor 10 mM mother liquor was formulated with 100% DMSO.
- test compound gradient dilution solution was prepared: 10 mM test compound stock was diluted 4 times in DMSO with a concentration of 2.5 mM, 625 ⁇ M, 156 ⁇ M, 39 ⁇ M, 9.8 ⁇ M, 2.5 ⁇ M. 2 ⁇ L of DMSO-diluted compound was added to 198 ⁇ L of 10% FBS-containing medium to prepare a 10-fold test substance with a maximum concentration of 100 ⁇ M and a DMSO concentration of 1% for a total of 7 concentration gradients.
- MDA-MB-435S medium L-15+10%FBS+0.01mg/mL insulin
- MCF-7 medium DMEM + 10% FBS + 0.01 mg / mL insulin
- Pancreatic digestion was carried out to 80% of cells (logarithmic growth phase), and the cells were collected by centrifugation.
- MDA-MB-435S and U87MG cells were resuspended in FBS-free medium, counted and adjusted to inoculate 96-well plates, MDA-MB-435S cells were seeded at 3000/well/81 ⁇ L, and U87MG cells were seeded at 4000/well/81 ⁇ L;
- the MCF-7 cells were resuspended in medium containing 1% FBS, counted and adjusted to inoculate 96-well plates, inoculated with 4000 cells/well/82 ⁇ L, and cultured in a 37 °C cell culture incubator;
- MDA-MB-435S and U87MG cells were added with FBS (9 ⁇ L) per well, and MCF-7 cells were supplemented with 8 ⁇ L of FBS per well to make the final concentration of FBS 10%;
- test substance (10 ⁇ L) at different concentrations to each well to make the final concentration of the test substance 10 ⁇ M, 2.5 ⁇ M, 625 nM, 156 nM, 39 nM, 9.8 nM, 2.5 nM, 3 replicate wells/group, culture at 37 °C. 72 hours;
- Normal cell control normal cells without any treatment
- OD blank control blank control value
- OD normal cell control normal cell control value
- Test article Part of the compound of the present invention, self-made, and its chemical name and preparation method are shown in the preparation examples of each compound.
- the reference drug LY2835219 self-made (prepared by the preparation method of the patent CN102264725A), has the structural formula as described in the background art.
- Test animals female nude mice (BALB/c), control drug: 3 / time point of administration, body weight 22-25 g / only; compound 1: 3 / time point of administration, body weight 22-25 g / only Compound 6-1: 6 / route of administration / test article, weight 18-26 g / only.
- MC methylcellulose
- SDS sodium lauryl sulfate
- pH 5.0 buffer Sodium dihydrogen phosphate dihydrate (1.56 g) was weighed, purified water was added to prepare a 50 mL solution, and the pH was adjusted to 5.0 with a sodium hydroxide solution.
- HPC hydroxypropylcellulose
- test solution is administered according to the following method:
- Control drug/compound 1, IV administration group 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 24, 30 h before administration, 10 mg/kg for PO administration: before administration, 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30 h after administration.
- Compound 1, PO was administered in the 100 mg/kg group: 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 h after administration.
- the control drug/Compound 1 was collected from the intraocular eye by 300 ⁇ L of whole blood at each time point, and the plasma was separated by centrifugation at 8000 rpm for 6 min in a high-speed centrifuge, and the plasma was frozen in a refrigerator at -80 °C.
- Compound 6-1 collected 60 ⁇ L of whole blood through intraocular fistula at each time point, and the blood was collected and placed in an anticoagulation tube containing K 2 EDTA anticoagulant, and the blood sample was centrifuged at 8000 rpm for 6 minutes to obtain a plasma sample.
- the plasma samples of the reference drug and Compound 1 were analyzed by protein precipitation: 50 ⁇ L of plasma was taken, 200 ⁇ L of internal standard (500 ng/mL acetonitrile solution containing warfarin), vortexed at 1500 rpm for 3 min, and then centrifuged at 13,000 rpm. 5 min, 100 ⁇ L of the supernatant was taken, 400 ⁇ L of water was added, vortexed, and analyzed by LC-MS/MS.
- the plasma samples of Compound 6-1 were analyzed by protein precipitation. The appropriate amount of plasma was added, a certain volume of internal standard solution was added, vortexed, the supernatant was taken, diluted with a certain volume of water, and vortexed, LC-MS/ MS injection analysis.
- AUC last represents the area under the curve of the drug 0 ⁇ t
- V ss represents the steady-state apparent distribution volume
- T max represents the peak plasma concentration
- Test article Compound 1 of the present invention, self-made, and its chemical name and preparation method are shown in the preparation examples of the respective compounds.
- Control drug LY2835219, self-made (prepared by the preparation method of CN102264725A), and its structural formula is as described in the background art.
- Test animals male SD rats, 3 / dose / test, weighing 200-240 g / only.
- Preparation method of solvent pH 4.0buffer take citric acid (21g), add water to dissolve, quantify to 1000mL to obtain a liquid, save for use; take disodium hydrogen phosphate (71.63g), add water to dissolve, quantify to 1000mL, get ethyl acetate, Save spare.
- the above liquid A 614.5 mL was mixed with the liquid B (385.5 mL), and shaken to obtain.
- the solution LY2835219 with a concentration of 13.5 mg/mL was prepared by using the solvent pH 4.0 buffer as a solvent.
- the above solutions 4-6 were respectively administered as drug solutions of 15 mg/kg, 45 mg/kg and 135 mg/kg of the compound 1PO.
- test solution is administered according to the following method:
- Collection time point PO 15 mg/kg group: 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 h after administration.
- PO 45 mg/kg group 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48, 56, 72 h after administration.
- PO 135 mg/kg group 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48, 56, 72, 96, 102 h after administration.
- Collection time point PO 15 mg/kg group: 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 h after administration.
- PO 45 mg/kg group 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48 h after administration.
- PO 135 mg/kg group 0.167, 0.5, 1, 2, 4, 6, 8, 24, 30, 48, 56, 72, 96 h after administration.
- the plasma samples of the reference drug and Compound 1 were analyzed by protein precipitation: 30 ⁇ L of plasma was added, and 200 ⁇ L of internal standard (containing PD0332991, the structural formula was Prepared according to the preparation method of patent CN101001857A, 50 ng/mL acetonitrile solution), vortex at 1500 rpm for 10 min, then centrifuge at 4000 rpm for 20 min, take 100 ⁇ L of the supernatant, add 100 ⁇ L of water, vortex and mix, then perform LC. - MS/MS analysis.
- T max represents the peak plasma concentration
- AUC last represents the area under the curve of the drug 0 ⁇ t
- Test article Compound 1 of the present invention, self-made, and its chemical name and preparation method are shown in the preparation examples of the respective compounds.
- Control drug LY2835219, self-made (prepared by the preparation method of CN102264725A), and its structural formula is as described in the background art.
- Test animals female nude mice (BALB/c), 8/dose group/test sample, weighing 19-27 g/only.
- Preparation method of blank solvent containing 0.5% MC and 0.1% SDS Weigh MC (2g), add ultrapure water (350mL) to dissolve, add SDS (0.4g), dilute to 400mL, mix well, 0.22 ⁇ m The filter was sterilized by filtration and stored at 4 ° C to obtain a blank solvent solution.
- control drug homogenization solution 1 with the concentration of 10mg/mL; take the control drug homogenization solution 1 (0.5mL), add the solvent (1.5 mL), vortex and mix to obtain a control drug homogenizing solution 2 with a concentration of 2.5 mg/mL.
- COLO205 cancer cells were cultured in RPMI-1640 medium containing inactivated 10% fetal bovine serum, 100 U/mL penicillin and 100 ⁇ g/mL streptomycin and 2 mM glutamine in a 37 ° C, 5% CO 2 incubator.
- the initial concentration of the cell culture was 5 ⁇ 10 5 /mL, and the cells were subcultured every 3 to 4 days after the cells were over. Tumor cells in the logarithmic growth phase are used for in vivo tumor inoculation.
- COLO205 tumor cells resuspended in PBS 1 ⁇ 10 7 / 0.1 mL were inoculated subcutaneously in the right flank of the experimental animals, and the animals were sacrificed when the tumor grew to 800 mm 3 to 1000 mm 3 , and the tumor was excised under sterile conditions.
- Tumor cells were passaged twice in mice in this manner, and the obtained primary cultured cells were inoculated subcutaneously into the right flank of the experimental animals, and each animal was inoculated with 5 ⁇ 10 6 / 0.1 mL.
- the tumors were administered in groups when the tumors were as long as about 100 mm 3 . Oral administration, the administration volume is 0.1 mL/10 g of the animal body weight.
- test solution is administered according to the following method:
- Blood collection The method of blood collection is blood collection in the eye.
- the blood collection/tumor time point design of the control drug and Compound 1 after the last administration (Day 22) was the same, and 8 nude mice in each dose group were divided into A and B groups:
- Group A (No. 1-4): 15 min, 1 h, 2 h, each mouse was sacrificed after 2 h of blood sampling;
- Group B (No. 5-8): 4h, 8h, 24h, each mouse was sacrificed after 24 hours of blood sampling;
- the plasma samples of the reference drug and Compound 1 were analyzed by protein precipitation: 50 ⁇ L of plasma was added, 150 ⁇ L of internal standard (containing dexamethasone 50 ng/mL in acetonitrile solution), vortexed at 1500 rpm for 3 min, and then centrifuged at 4000 rpm. After 20 min, 100 ⁇ L of the supernatant was taken, 100 ⁇ L of water was added, vortexed, and then subjected to LC-MS/MS analysis.
- internal standard containing dexamethasone 50 ng/mL in acetonitrile solution
- AUC last represents the area under the curve of the drug 0 ⁇ t
- T max represents the peak plasma concentration
- Test article Compound 1 of the present invention, self-made, and its chemical name and preparation method are shown in the preparation examples of the respective compounds.
- Control drug LY2835219, self-made (prepared by the preparation method of CN102264725A), and its structural formula is as described in the background art.
- Test animals male SD rats, 3 / test / time point, weighing 250-300 g / only.
- the reference drug (108.22 mg) was weighed, and the solvent (36.07 mL) was added and ground to homogenize the suspension to obtain a homogeneous solution 1.
- This solution was used as a control drug LY2835219 rat PO administration solution.
- test solution is administered separately according to the following methods:
- control drug and Compound 1 PO was subjected to cardiac puncture at 2, 4, 24, and 48 h after administration, and about 8 mL of whole blood was collected, and a centrifuge tube containing K 2 EDTA as an anticoagulant was placed, and cerebrospinal fluid was collected at the same time. Brain tissue, 3 at each time point. Whole blood samples were collected and centrifuged at 3000 rpm in a high-speed centrifuge. The plasma was separated by centrifugation at 4 ° C for 10 min, and the plasma was frozen in a -80 ° C refrigerator. After the sample was collected, the concentrations of the control drug and Compound 1 in plasma, brain tissue, cerebrospinal fluid, and the like were measured.
- the plasma samples of the control drug and Compound 1 administration group were analyzed by protein precipitation method: the sample to be tested (-80 ° C) was taken out from the refrigerator, vortexed at room temperature for 3 min, and 30 ⁇ L of plasma was taken.
- the internal standard including PD0332991, 25 ng/mL acetonitrile solution 200 ⁇ L, vortex at 1500 rpm for 10 min, then centrifuge at 4000 rpm for 20 min, take the supernatant (100 ⁇ L), add water (100 ⁇ L), vortex and mix, then perform LC-MS /MS analysis.
- the brain tissue samples and cerebrospinal fluid samples of the control drug and Compound 1 administration group were analyzed by protein precipitation method: the sample to be tested was taken out from the refrigerator (-80 ° C), naturally fused at room temperature, vortexed for 3 min, and the brain tissue after homogenization was taken.
- AUC last represents the area under the curve of the drug 0 ⁇ t
- T max represents the peak plasma concentration
- the compound of the present invention evaluates the permeability of the blood-brain barrier in rats compared with the control drug. It can effectively enter the brain tissue from plasma, and the exposure of the drug in the cerebrospinal fluid is significantly higher than the control drug LY2835219.
- Test article The compound of the present invention, self-made, and its chemical name and preparation method are shown in the preparation examples of each compound.
- Control drug LY2835219, self-made (prepared by the preparation method of CN102264725A), and its structural formula is as described in the background art.
- Test animals female nude mice (BALB/c), 10/dose group/test sample, weighing 18-22 g/only.
- Preparation of solvent containing 0.5% MC take appropriate amount of MC, add a certain volume of ultrapure water, dissolve, and mix well, that is, solvent 1 with MC content of 0.5%;
- Preparation of solvent containing 0.5% MC and 0.1% SDS Weigh the appropriate amount of MC and SDS, add a certain volume of ultrapure water, dissolve and mix well, then obtain solvent 2 with MC content of 0.5% and SDS content of 0.1%. ;
- control drug homogenization solution 1 Take the reference drug (508.87mg) and SDS (39.37mg), dilute with solvent 1 (39.37mL), grind evenly to obtain the control drug homogenization solution 1 with a concentration of 10.1mg/mL; take the control drug homogenization solution 1 ( 13.125 mL), solvent 2 (13.125 mL) was added, and the mixture was uniformly ground to obtain a control drug homogenizing solution 2 having a concentration of 5.0 mg/mL.
- Compound 1 (931.77 mg) and SDS (45.9 mg) were taken, diluted with solvent 1 (45.9 mL), and uniformly ground to obtain Compound 1 homogeneous solution 1 at a concentration of 20.0 mg/mL; Compound 1 (20.0 mg/mL) was taken.
- a homogeneous solution (19.69 mL), adding solvent 2 (19.69 mL), and grinding uniformly to obtain a homogeneous solution of Compound 1 at a concentration of 10.0 mg/mL; a homogeneous solution of Compound 1 (10.0 mg/mL) was obtained ( 13.125 mL), solvent 2 (13.125 mL) was added, and the mixture was uniformly ground to obtain a compound 1 homogeneous solution 3 having a concentration of 5.0 mg/mL.
- U87MG cells derived from ATCC were cultured in MEM medium containing 10% fetal calf serum, and the cells were digested according to a conventional method using trypsin containing EDTA, subcultured twice a week, and placed at 37 ° C, 5% CO 2 culture. Continue to train in the box.
- the logarithmic growth phase tumor cells were collected, and the concentration of U87MG cells was adjusted to 5 ⁇ 10 7 /mL in a ratio of 1:1 with PBS and Matrigel.
- 0.1 mL of the cell suspension was inoculated into the right side of each mouse near the back subcutaneously with a 1 mL syringe. .
- the tumor volume was observed and measured.
- the average tumor volume of U87MG reached about 200 mm 3 8 days after inoculation, and then the tumor cell-bearing mice were grouped and administered by oral administration.
- the dose was 0.1 mL of the animal body weight. /10g.
- test solution is administered according to the following method:
- Blood collection The method of blood collection is blood collection in the eye.
- the blood collection/tumor time point design of the control drug and Compound 1 after the last administration (Day 22) was the same.
- One of the 10 nude mice in each dose group was reserved, and the other 9 were divided into three groups: A, B, and C:
- Group A (No. 1-3): before the drug, 1h, 2h, each mouse was sacrificed after 2 hours of blood sampling;
- Group B (No. 4-6): 15 min, 4 h, 6 h, each mouse was sacrificed after 6 hours of blood sampling;
- Group C (No. 7-9): 30 min, 10 h, 24 h, each mouse was sacrificed after 24 hours of blood sampling;
- the plasma samples of the reference drug and Compound 1 were analyzed by protein precipitation: 30 ⁇ L of plasma was taken into a square 96 deep well plate, and 200 ⁇ L of internal standard (PD0332991) in acetonitrile (25 ng/mL) was added, and vortexed at 1500 rpm for 3 min. Then, centrifuge at 4000 rpm for 20 min, take 100 ⁇ L of the supernatant, add 100 ⁇ L of water, vortex and mix, and analyze by LC-MS/MS.
- internal standard PD0332991
- acetonitrile 25 ng/mL
- AUC last represents the area under the curve of the drug 0 ⁇ t
- T mzx represents peak plasma concentration
- 2,5-Difluoro-4-iodopyridine (4.82 g, 20 mmol) was dissolved in dimethyl sulfoxide (40 mL), and aqueous ammonia (40 mL) was added under stirring, and the mixture was stirred at 90 ° C for 12 h. Ethyl acetate (150 mL) was added, and the title compound was evaporated. Rate 50%).
- 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole (9.0 g, 33.2 mmol), boronic acid pinacol ester (12.65 g, 49.8 mmol), Palladium acetate (840 mg, 3.75 mmol), tricyclohexylphosphine (1.63 g, 5.8 mmol) and potassium acetate (9.78 g, 99.8 mmol) were added to dimethyl sulfoxide (60 mL) and heated to 80 ° C under nitrogen. 6h. Water (200 mL) and ethyl acetate (200 mL) were added, and the aqueous layer was evaporated, evaporated, evaporated, evaporated, evaporated, The title compound (6.0 g, yield 56.8%).
- tert-Butyl 4-(2-(bis(4-methoxybenzyl)amino)pyrimidin-5-yl)piperazine-1-carboxylate (6.2 g, 11.9 mmol) was dissolved in dichloromethane (30 mL) And a mixed solution of trifluoroacetic acid (30 mL), stirred at room temperature for 30 minutes, and the solvent was removed by rotary evaporation. Dichloromethane was evaporated and the solvent was evaporated again to give a crude material (m. The product was not purified and was used for the next step.
- Example 6-1 N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-yl) Preparation of 5-(-(cis)-5-methylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-yl)methyl)pyrimidin-2-amine (Compound 6-1)
- Example 6-2 5-(((cis)-5-ethylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-yl)methyl)-N-(5-fluoro- Preparation of 4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-ylpyrimidin-2-amine (Compound 6-2)
- tert-Butyl (cis)-5-ethylhexahydropyrrolo[3,4-c]pyrrole-2(1H)-formate (317 mg, 1.32 mmol) was dissolved in dichloromethane (3 mL) and The mixed solution of fluoroacetic acid (3 mL) was stirred at room temperature for 30 minutes, and the solvent was evaporated to dryness. The product was taken to the next step without purification.
- Example 7 N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-yl)-5 Preparation of (((cis)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)methyl)pyrimidin-2-amine (Compound 7)
- Example 8 (Exo)-3-((2-((5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-) Preparation of pyridin-2-yl)amino)pyrimidin-5-yl)methyl)-3-azabicyclo[3.1.0]hexane-6-amine (Compound 8)
- tert-Butyl (exo)-6-((benzyloxycarbonyl)amino)-3-azabicyclo[3.1.0]hexane-3-carboxylate (578 mg, 1.74 mmol) was dissolved in dichloromethane. In 10 mL), trifluoroacetic acid (5 mL) was added, and the mixture was stirred at room temperature for 3 hr.
- N,N-bis(4-methoxybenzyl)-5-(4-methylpiperazinyl-1yl)pyrimidine-2-amine 800 mg, 1.8 mmol
- trifluoroacetic acid 10 mL
- methyl chloride 10 mL
Abstract
Description
Claims (23)
- 通式(I′)所示的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自C1-6烷基、C1-6烷氧基或任选被Q1取代的3-8元环烷基,Q1选自C1-6烷基或C1-6烷氧基;R2选自C1-6烷基、C1-6烷氧基、氰基、氨基甲酰基或C1-6烷基羰基氨基;R3和R5分别独立地选自卤素或氢,且R3和R5至少一个为卤素;R4选自任选被Q2取代的3-8元杂环基、6-14元稠杂环基、5-8元杂芳基、6-14元稠杂芳基、苯基、萘基、6-12元桥杂环基或6-12元螺杂环基;Q2选自氨基,羟基,卤素,三氟甲基,氰基,C1-6烷氧基,C1-6烷基磺酰基,C1-6烷基磺酰氨基,二C1-6烷基氨基,或任选被取代基取代的C1-6烷基、3-8元环烷基、3-8元杂环基或6-9元桥杂环基,所述取代基选自氨基、羟基、卤素、三氟甲基、氰基、C1-6烷基、C1-6烷氧基、C1-6烷基氨基、二C1-6烷基氨基、C1-6烷基磺酰基、3-8元杂环基或3-8元环烷基;n选自0、1、2、3、4或5。
- 权利要求1的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自C1-4烷基或C1-4烷氧基;R2选自C1-4烷基、C1-4烷氧基、氰基、氨基甲酰基或C1-4烷基羰基氨基;R3和R5分别独立地选自卤素;R4选自任选被Q2取代的5-6元含氮杂环基;所述的“5-6元含氮杂环基”优选为“6元含氮杂环基”;Q2选自氨基,羟基,卤素,三氟甲基,氰基,C1-4烷氧基,二C1-4烷基氨基,或任选被 取代基取代的C1-4烷基、3-6元环烷基或3-6元杂环基,所述取代基选自氨基、羟基、卤素、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4烷基氨基、二C1-4烷基氨基或3-6元环烷基;n选自0。
- 权利要求1所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中所述化合物具有下述式(I)的结构,其中,A1和A2分别独立地选自氮;R1选自C1-6烷基、C1-6烷氧基或任选被Q1取代的3-8元环烷基,其中Q1选自C1-6烷基或C1-6烷氧基;R2选自C1-6烷基、C1-6烷氧基、氰基、氨基甲酰基或C1-6烷基羰基氨基;R3和R5分别独立地选自卤素或氢,且R3和R5至少一个为卤素;R4选自任选被Q2取代的3-8元杂环基、6-14元稠杂环基、5-8元杂芳基、6-14元稠杂芳基、苯基、萘基、6-12元桥杂环基或6-12元螺杂环基,其中Q2选自氨基、羟基、卤素、三氟甲基、氰基、C1-6烷基、C1-6烷氧基、3-8元杂环基或6-9元桥杂环基。
- 如权利要求4所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自C1-4烷基或C1-4烷氧基;R2选自C1-4烷基、C1-4烷氧基、氰基、氨基甲酰基或C1-4烷基羰基氨基;R3和R5分别独立地选自卤素;R4选自任选被Q2取代的5-7元杂环基、6-11元稠杂环基、6-11元桥杂环基或6-11元螺杂环基,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、C1-4烷氧基、5-6元杂环基或7-9元桥杂环基。
- 如权利要求5所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中A1和A2分别独立地选自氮;R1选自异丙基;R2选自甲基、甲氧基、氰基、氨基甲酰基或乙酰氨基;R3和R5各自是氟;R4选自任选被Q2取代的5-6元杂环基,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、C1-4烷氧基、6元杂环基或8元桥杂环基。
- 如权利要求6所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,R2选自甲基;R4选自任选被Q2取代的5-6元含氮杂环基,所述5-6元含氮杂环基通过氮原子与通式(I)中的亚甲基连接,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、C1-4烷氧基或8元 含氮桥杂环基;所述的5-6元含氮杂环基优选为含1-2个氮原子的5-6元含氮杂环基。
- 如权利要求5所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自异丙基;R2选自甲基、甲氧基、氰基、氨基甲酰基或乙酰氨基;R3和R5各自是氟;R4选自任选被Q2取代的7-9元桥杂环基,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、6元杂环基或8元桥杂环基。
- 如权利要求9所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,R2选自甲基;R4选自任选被Q2取代的7-9元含氮桥杂环基,所述7-9元含氮桥杂环基通过氮原子与通式(I)中的亚甲基连接,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基或6元含氮杂环基;所述7-9元含氮桥杂环基优选为含1-2个氮原子的7-9元含氮桥杂环基。
- 如权利要求5所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自异丙基;R2选自甲基、甲氧基、氰基、氨基甲酰基或乙酰氨基;R3和R5各自是氟;R4选自任选被Q2取代的6-10元稠杂环基,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、6元杂环基或8元桥杂环基。
- 如权利要求12所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,R2选自甲基;R4选自任选被Q2取代的含有1、2或3个相同或不同杂原子的6-10元稠杂环基,所述杂原子优选选自氮原子和氧原子,并且含有至少一个氮原子,所述6-10元稠杂环基通过氮原子与通式(I)中的亚甲基连接,其中Q2选自氨基、羟基、三氟甲基、氰基或C1-4烷基。
- 如权利要求5所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,A1和A2分别独立地选自氮;R1选自异丙基;R2选自甲基、甲氧基、氰基、氨基甲酰基或乙酰氨基;R3和R5各自是氟;R4选自任选被Q2取代的7-11元螺杂环基,其中Q2选自氨基、羟基、三氟甲基、氰基、C1-4烷基、6元杂环基或8元桥杂环基。
- 如权利要求15所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,其中,R2选自甲基;R4选自任选被Q2取代的7-11元含氮螺杂环基,所述7-11元含氮螺杂环基通过氮原子与通式(I)中的亚甲基连接,其中Q2选自氨基、羟基、三氟甲基、氰基或C1-4烷基;所述7-11元含氮螺杂环基优选为含1-2个氮原子的7-11元含氮螺杂环基。
- 一种药物组合物,其包含权利要求1-18中任一项所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体,以及任选的一种或多种药用载体。
- 如权利要求19所述的药物组合物,其还包含一种或多种额外的抗肿瘤剂和/或免疫抑制剂。
- 如权利要求20所述的药物组合物,其中所述额外的抗肿瘤剂和/或免疫抑制剂选自下述中的一种或多种:甲氨蝶呤、卡培他滨、吉西他滨、去氧氟尿苷、培美曲塞二钠、帕唑帕尼、伊马替尼、埃罗替尼、拉帕替尼、吉非替尼、凡德他尼、赫赛汀、贝伐单抗、利妥昔单抗、曲妥珠单抗、紫杉醇、长春瑞滨、多西他赛、多柔比星、羟基喜树碱、丝裂霉素、表柔比星、吡柔比星、博来霉素、来曲唑、他莫西芬、氟维司群、曲谱瑞林、氟他胺、亮丙瑞林、阿那曲唑、异环磷酰胺、白消安、环磷酰胺、卡莫司汀、尼莫司汀、司莫司汀、氮芥、马法兰、瘤可宁、卡铂、顺铂、奥沙利铂、络铂、拓扑特肯、喜树碱、拓扑替康、依维莫司、西罗莫斯、特癌适、6-巯基嘌呤、6-硫鸟嘌呤、硫唑嘌呤、菌素D、柔红霉素、阿霉素、米托蒽醌、争光霉素、普卡霉素和氨鲁米特。
- 权利要求1-18任一项所述的化合物、其药学上可接受的盐、其酯、其溶剂化物或它们的立体异构体用于制备药物的用途,所述药物用于治疗和/或预防受试者中由CDK4/6激酶 介导的癌症相关疾病。
- 如权利要求22所述的用途,其中所述癌症相关疾病选自脑瘤、肺癌、鳞状上皮细胞癌、膀胱癌、胃癌、卵巢癌、腹膜癌、胰腺癌、乳腺癌、头颈癌、子***、子宫内膜癌、直肠癌、肝癌、肾癌、食管腺癌、食管鳞状细胞癌、***癌、雌性生殖道癌、原位癌、淋巴瘤、神经纤维瘤、甲状腺癌、骨癌、皮肤癌、脑癌、结肠癌、睾丸癌、胃肠道间质瘤、***肿瘤、肥大细胞肿瘤、多发性骨髓瘤、黑色素瘤、胶质瘤或肉瘤。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2016130986A RU2670762C2 (ru) | 2013-12-31 | 2014-12-30 | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
ES14876154.7T ES2687477T3 (es) | 2013-12-31 | 2014-12-30 | Inhibidor de quinasa y su uso |
AU2014375500A AU2014375500B2 (en) | 2013-12-31 | 2014-12-30 | Kinase inhibitor and use thereof |
KR1020167021119A KR101787680B1 (ko) | 2013-12-31 | 2014-12-30 | 키나아제 억제제 및 이의 용도 |
CN201480065837.2A CN105916848B (zh) | 2013-12-31 | 2014-12-30 | 激酶抑制剂及其用途 |
PL14876154T PL3091008T3 (pl) | 2013-12-31 | 2014-12-30 | Inhibitor kinazy i jego zastosowanie |
EP14876154.7A EP3091008B1 (en) | 2013-12-31 | 2014-12-30 | Kinase inhibitor and use thereof |
JP2016543135A JP6263269B2 (ja) | 2013-12-31 | 2014-12-30 | キナーゼ阻害剤及びその使用 |
US15/108,903 US9796701B2 (en) | 2013-12-31 | 2014-12-30 | Kinase inhibitor and use thereof |
CA2935103A CA2935103C (en) | 2013-12-31 | 2014-12-30 | Kinase inhibitor and use thereof |
HK16109747.9A HK1223089A1 (zh) | 2013-12-31 | 2016-08-15 | 激酶抑制劑及其用途 |
US15/704,542 US9949976B2 (en) | 2013-12-31 | 2017-09-14 | Kinase inhibitor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310749417 | 2013-12-31 | ||
CN201310749417.3 | 2013-12-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/108,903 A-371-Of-International US9796701B2 (en) | 2013-12-31 | 2014-12-30 | Kinase inhibitor and use thereof |
US15/704,542 Continuation-In-Part US9949976B2 (en) | 2013-12-31 | 2017-09-14 | Kinase inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015101293A1 true WO2015101293A1 (zh) | 2015-07-09 |
Family
ID=53493247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/095615 WO2015101293A1 (zh) | 2013-12-31 | 2014-12-30 | 激酶抑制剂及其用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9796701B2 (zh) |
EP (1) | EP3091008B1 (zh) |
JP (1) | JP6263269B2 (zh) |
KR (1) | KR101787680B1 (zh) |
CN (1) | CN105916848B (zh) |
AU (1) | AU2014375500B2 (zh) |
CA (1) | CA2935103C (zh) |
ES (1) | ES2687477T3 (zh) |
HK (1) | HK1223089A1 (zh) |
HU (1) | HUE039504T2 (zh) |
PL (1) | PL3091008T3 (zh) |
RU (1) | RU2670762C2 (zh) |
WO (1) | WO2015101293A1 (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016173557A1 (zh) * | 2015-04-30 | 2016-11-03 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
WO2016173505A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
WO2017133701A1 (en) * | 2016-02-06 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
CN107827875A (zh) * | 2017-09-25 | 2018-03-23 | 文韬创新药物研究(北京)有限责任公司 | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
WO2019144759A1 (zh) * | 2018-01-29 | 2019-08-01 | 海南轩竹医药科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
CN110092775A (zh) * | 2018-01-29 | 2019-08-06 | 海南轩竹医药科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
WO2019206154A1 (zh) | 2018-04-24 | 2019-10-31 | 上海海雁医药科技有限公司 | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 |
JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
WO2020125513A1 (zh) | 2018-12-19 | 2020-06-25 | 凯复制药有限公司 | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 |
WO2020224609A1 (zh) * | 2019-05-08 | 2020-11-12 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
CN112010839A (zh) * | 2019-05-31 | 2020-12-01 | 轩竹生物科技有限公司 | 靶向丝/苏氨酸激酶抑制剂的晶型 |
US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022143969A1 (zh) * | 2020-12-31 | 2022-07-07 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
US11510920B2 (en) | 2016-10-28 | 2022-11-29 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
WO2023109741A1 (zh) * | 2021-12-13 | 2023-06-22 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2968290T (pt) | 2013-03-15 | 2019-11-27 | G1 Therapeutics Inc | Protecção transitória de células normais durante a quimioterapia |
US9949976B2 (en) | 2013-12-31 | 2018-04-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
CN110325191A (zh) * | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
SG11202005937QA (en) | 2018-01-08 | 2020-07-29 | G1 Therapeutics Inc | G1t38 superior dosage regimes |
SG11202006748RA (en) * | 2018-01-29 | 2020-08-28 | Beta Pharma Inc | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
US20210038661A1 (en) * | 2018-03-05 | 2021-02-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
US11622966B2 (en) | 2018-05-25 | 2023-04-11 | A2A Pharmaceuticals, Inc. | Highly potent TACC3 inhibitor as a novel anticancer drug candidate |
CN109180589A (zh) * | 2018-10-16 | 2019-01-11 | 武汉工程大学 | 玻玛西尼中间体的制备方法 |
EP3917532A4 (en) * | 2019-01-29 | 2022-09-28 | Beta Pharma, Inc. | 2H-INDAZOLE DERIVATIVES USED AS THERAPEUTIC AGENTS AGAINST BRAIN CANCERS AND BRAIN METASTASIS |
CN112535686B (zh) * | 2019-09-20 | 2022-06-14 | 山东轩竹医药科技有限公司 | 激酶抑制剂的新用途 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN114748479B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
JP2024518711A (ja) * | 2021-04-12 | 2024-05-02 | エーツーエー ファーマシューティカルズ インコーポレーテッド | 癌を処置するための組成物及び方法 |
WO2024051702A1 (zh) * | 2022-09-05 | 2024-03-14 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
CN115650968B (zh) * | 2022-12-27 | 2023-03-21 | 英矽智能科技(上海)有限公司 | 作为cdk选择性抑制剂的新型哒嗪酮化合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001857A (zh) | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
CN102186856A (zh) * | 2008-08-22 | 2011-09-14 | 诺瓦提斯公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
CN102264725A (zh) | 2008-12-22 | 2011-11-30 | 伊莱利利公司 | 蛋白激酶抑制剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
ATE353013T1 (de) | 2002-02-19 | 2007-02-15 | Pfizer Italia Srl | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel |
US7947695B2 (en) * | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
JP2009507020A (ja) * | 2005-09-06 | 2009-02-19 | スミスクライン ビーチャム コーポレーション | Plk調節物質としてのルベンゾイミダゾールチオフェン化合物 |
AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
JP5640006B2 (ja) * | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | ヒストン脱アセチル化酵素および/またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
-
2014
- 2014-12-30 AU AU2014375500A patent/AU2014375500B2/en active Active
- 2014-12-30 ES ES14876154.7T patent/ES2687477T3/es active Active
- 2014-12-30 JP JP2016543135A patent/JP6263269B2/ja active Active
- 2014-12-30 HU HUE14876154A patent/HUE039504T2/hu unknown
- 2014-12-30 WO PCT/CN2014/095615 patent/WO2015101293A1/zh active Application Filing
- 2014-12-30 RU RU2016130986A patent/RU2670762C2/ru active
- 2014-12-30 PL PL14876154T patent/PL3091008T3/pl unknown
- 2014-12-30 US US15/108,903 patent/US9796701B2/en active Active
- 2014-12-30 KR KR1020167021119A patent/KR101787680B1/ko active IP Right Grant
- 2014-12-30 EP EP14876154.7A patent/EP3091008B1/en active Active
- 2014-12-30 CA CA2935103A patent/CA2935103C/en active Active
- 2014-12-30 CN CN201480065837.2A patent/CN105916848B/zh active Active
-
2016
- 2016-08-15 HK HK16109747.9A patent/HK1223089A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101001857A (zh) | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
CN102186856A (zh) * | 2008-08-22 | 2011-09-14 | 诺瓦提斯公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
CN102264725A (zh) | 2008-12-22 | 2011-11-30 | 伊莱利利公司 | 蛋白激酶抑制剂 |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10450316B2 (en) | 2015-04-28 | 2019-10-22 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
WO2016173505A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
RU2732952C2 (ru) * | 2015-04-28 | 2020-09-24 | Цунцин Фокон Фармасьютикал Ко., Лтд. | Ингибитор некоторых протеинкиназ |
EP3288931B1 (en) | 2015-04-28 | 2019-11-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
CN106083823A (zh) * | 2015-04-30 | 2016-11-09 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
WO2016173557A1 (zh) * | 2015-04-30 | 2016-11-03 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
WO2017133701A1 (en) * | 2016-02-06 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
JP2019533022A (ja) * | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US11510920B2 (en) | 2016-10-28 | 2022-11-29 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
CN107827875A (zh) * | 2017-09-25 | 2018-03-23 | 文韬创新药物研究(北京)有限责任公司 | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
CN107827875B (zh) * | 2017-09-25 | 2021-07-09 | 文韬创新药物研究(北京)有限责任公司 | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
WO2019144759A1 (zh) * | 2018-01-29 | 2019-08-01 | 海南轩竹医药科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
KR102531772B1 (ko) | 2018-01-29 | 2023-05-11 | 수안주 바이오파마슈티컬 컴퍼니 리미티드 | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 |
KR20200116132A (ko) * | 2018-01-29 | 2020-10-08 | 수안주 (하이난) 바이오파마슈티컬 컴퍼니 리미티드 | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 |
CN110092775B (zh) * | 2018-01-29 | 2021-09-10 | 轩竹生物科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
CN110092775A (zh) * | 2018-01-29 | 2019-08-06 | 海南轩竹医药科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
US11299474B2 (en) | 2018-01-29 | 2022-04-12 | Xuanzhu Biopharmaceutical Co., Ltd. | Crystal form targeting CDK4/6 kinase inhibitor |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
WO2019206154A1 (zh) | 2018-04-24 | 2019-10-31 | 上海海雁医药科技有限公司 | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 |
WO2020125513A1 (zh) | 2018-12-19 | 2020-06-25 | 凯复制药有限公司 | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 |
CN113811302A (zh) * | 2019-05-08 | 2021-12-17 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
CN113811302B (zh) * | 2019-05-08 | 2023-12-29 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
WO2020224609A1 (zh) * | 2019-05-08 | 2020-11-12 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
CN112010839B (zh) * | 2019-05-31 | 2022-06-17 | 轩竹生物科技股份有限公司 | 靶向丝/苏氨酸激酶抑制剂的晶型 |
CN112010839A (zh) * | 2019-05-31 | 2020-12-01 | 轩竹生物科技有限公司 | 靶向丝/苏氨酸激酶抑制剂的晶型 |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022143969A1 (zh) * | 2020-12-31 | 2022-07-07 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2023109741A1 (zh) * | 2021-12-13 | 2023-06-22 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
US9796701B2 (en) | 2017-10-24 |
RU2016130986A3 (zh) | 2018-05-25 |
EP3091008B1 (en) | 2018-06-27 |
JP2017501187A (ja) | 2017-01-12 |
RU2670762C2 (ru) | 2018-10-25 |
PL3091008T3 (pl) | 2018-12-31 |
CN105916848B (zh) | 2018-01-09 |
AU2014375500B2 (en) | 2017-03-16 |
HUE039504T2 (hu) | 2019-01-28 |
US20160332989A1 (en) | 2016-11-17 |
HK1223089A1 (zh) | 2017-07-21 |
KR101787680B1 (ko) | 2017-10-19 |
CN105916848A (zh) | 2016-08-31 |
AU2014375500A1 (en) | 2016-08-18 |
ES2687477T3 (es) | 2018-10-25 |
CA2935103A1 (en) | 2015-07-09 |
EP3091008A1 (en) | 2016-11-09 |
KR20160104072A (ko) | 2016-09-02 |
EP3091008A4 (en) | 2017-06-28 |
CA2935103C (en) | 2018-08-28 |
JP6263269B2 (ja) | 2018-01-17 |
RU2016130986A (ru) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015101293A1 (zh) | 激酶抑制剂及其用途 | |
US10919913B2 (en) | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | |
CN110382499B (zh) | Fgfr抑制剂及其应用 | |
CN112203653A (zh) | 用于治疗亨廷顿氏病的化合物 | |
CN114163437A (zh) | 经取代的吡唑并[1,5-a]吡啶化合物作为ret激酶抑制剂 | |
CN112654625A (zh) | 用于治疗亨廷顿氏病的杂环和杂芳基化合物 | |
CN109422754A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
CN114245794A (zh) | 用于治疗亨廷顿氏病的化合物 | |
KR20210099611A (ko) | 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도 | |
WO2014113191A1 (en) | Hedgehog pathway signaling inhibitors and therapeutic applications thereof | |
CN103038233A (zh) | 吡啶酮和氮杂吡啶酮化合物及使用方法 | |
CN104910137A (zh) | Cdk激酶抑制剂 | |
CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
KR20210120054A (ko) | Akt 억제제 | |
TW201927787A (zh) | 吡咯並三嗪化合物及抑制tam激酶之方法 | |
US10894793B2 (en) | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | |
US9949976B2 (en) | Kinase inhibitor and use thereof | |
WO2023093728A1 (zh) | Brm选择性降解剂化合物及其应用 | |
TW202321256A (zh) | 8-氧-3-氮雜雙環[3.2.1]辛烷類化合物或其鹽及其製備方法和用途 | |
WO2023104155A1 (zh) | E3泛素连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14876154 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2935103 Country of ref document: CA Ref document number: 2016543135 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15108903 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014876154 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014876154 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167021119 Country of ref document: KR Kind code of ref document: A Ref document number: 2016130986 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014375500 Country of ref document: AU Date of ref document: 20141230 Kind code of ref document: A |